GenScript

Atezolizumab Monoclonal Antibody (43H11), Biotin, MonoRab™

Product Image Gallery

Atezolizumab Antibody in ELISA (ELISA) — Standard curve of Atezolizumab Sandwich ELISA. The Atezolizumab Sandwich ELISA assay is developed by using MonoRab™ Anti-Atezolizumab Antibody (55D8), mAb, Rabbit (GenScript, A01984-40) and MonoRab™ Anti-Atezolizumab Antibody (43H11) [Biotin] (Genscript, A01986-40) as the capture and detection antibodies, respectively. The Sensitivity of detecting Atezolizumab is up to 156 pg/mL.

Product Details

A01986-40

Applications

Tested Dilution

Publications

ELISA (ELISA)

0.01-0.1 µg/mL

Product Specifications

Species Reactivity

Chemical

Host/Isotype

Rabbit / IgG

Class

Monoclonal

Type

Antibody

Clone

43H11

Immunogen

Atezolizumab

Conjugate

Biotin

Form

Lyophilized

Purification

Protein A

Storage buffer

PBS, pH 7.4, with 1% BSA

Contains

0.02% sodium azide

Storage conditions

-20°C or -80°C if preferred

Product Specific Information

Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.

Atezolizumab is a fully humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of metastatic non-small cell lung cancer (NSCLC). It binds to the protein programmed cell death-ligand 1 (PD-L1) on several tumors. Atezolizumab has ability to block the binding of PD-L1 with PD-1 and CD80 receptors (B7-1Rs), which has a positive effect on improving an anti-tumor response.GenScript MonoRab™ Anti-Atezolizumab Antibody (43H11), mAb, Rabbit is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a rabbit immunized with Atezolizumab.

Target Information

Atezolizumab is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1). Atezolizumab blocks the interaction of PD-L1 with programmed cell death protein 1 (PD-1) and CD80 receptors (B7-1Rs). PD-L1 can be highly expressed on certain tumors, which is thought to lead to reduced activation of immune cells (cytotoxic T-cells in particular) that might otherwise recognize and attack the cancer. Inhibition of PD-L1 by atezolizumab can remove this inhibitor effect and thereby engender an anti-tumor response. It is one of several ways to block inhibitory signals related to T-cell activation, a more general strategy known as "immune checkpoint inhibition."

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

References (0)

Have you cited this product in a publication?

Let us know so we can reference it here.

Cite this product

Bioinformatics

Protein Aliases: MPDL3280A; RG7446; Tecentriq